Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union (EU). Nemluvio is now ...
Nemluvio is the first approved monoclonal antibody that specifically targets IL-31 receptor alpha, inhibiting the signaling of IL-31, which drives itch and is involved in inflammation and skin barrier ...
New 2-year data show the long-term effects of bimekizumab on hidradenitis suppurativa, indicating its potential as a valuable ...
In 2020-2021, a mysterious skin disease affected fishermen in Senegal. High levels of Portimine A toxin, produced by the ...
A new slew of beauty products are focused on strengthening the skin barrier to mitigate other issues. Here, experts explain ...
More information about the 2025 AAAAI / WAO Joint Congress can be accessed here.
Atopic dermatitis is a chronic inflammatory skin disease affecting a growing number of people worldwide. Marked by persistent ...
Psoriasis is a chronic skin disease that manifests itself mainly with skin symptoms (dryness, itching, scaly skin, abnormal patches and plaques). It affects about 2% of the population and is mediated ...
Mayo Clinic researchers have identified a targeted therapy that could bring relief to people living with lichen planus, a ...
Scientists have progressed from merely provoking an anti-cancer immune response to designing it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback